Quick Answer
Replimune Group, Inc. reported Net Income of -$247.30 million for fiscal year 2025.
Replimune Group, Inc. — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Net Income | -$247.30M -14.6% |
-$215.79M -23.8% |
-$174.28M -47.7% |
-$118.04M -46.0% |
-$80.87M -53.7% |
-$52.62M -70.7% |
| Diluted EPS | -$3.07 +5.2% |
-$3.24 -8.4% |
-$2.99 -32.3% |
-$2.26 -29.1% |
-$1.75 | — |
| Total Assets | $551.33M +13.0% |
$487.72M -24.6% |
$646.59M +40.2% |
$461.19M -15.1% |
$543.10M +132.0% |
$234.10M +51.7% |
| Cash and Equivalents | $111.12M +49.2% |
$74.46M -49.2% |
$146.59M +38.4% |
$105.95M -42.0% |
$182.52M +206.8% |
$59.50M +131.5% |
| Long-Term Debt | $46.38M +3.5% |
$44.81M +56.4% |
$28.65M | $0.00 | — | $9.80M |
| Stockholders Equity | $415.84M +11.0% |
$374.51M -32.6% |
$555.29M +35.0% |
$411.23M -17.5% |
$498.73M +171.5% |
$183.72M +33.3% |
| R&D Expense | $189.45M +8.3% |
$174.96M +38.3% |
$126.53M +59.1% |
$79.55M +40.2% |
$56.75M +46.4% |
$38.76M +74.8% |
| Operating Income | -$261.63M -11.4% |
-$234.77M -32.6% |
-$177.08M -49.7% |
-$118.31M -48.0% |
-$79.95M -42.3% |
-$56.20M -81.6% |
| Shares Outstanding | 77.09M +25.5% |
61.42M +8.4% |
56.68M +19.7% |
47.34M +1.7% |
46.57M +27.0% |
36.67M +15.8% |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Net Income | December 31, 2025 | -$70.93M | -6.9% | +14.6% |
| Diluted EPS | December 31, 2025 | -$0.77 | +2.5% | +14.4% |
| Total Assets | December 31, 2025 | $333.59M | -44.7% | -14.3% |
| Cash and Equivalents | December 31, 2025 | $122.95M | -28.6% | +20.2% |
| Long-Term Debt | December 31, 2025 | $47.63M | +3.6% | +0.9% |
| Stockholders Equity | December 31, 2025 | $210.54M | -56.4% | -20.0% |
| R&D Expense | December 31, 2025 | $53.14M | +10.7% | -8.2% |
| Operating Income | December 31, 2025 | -$71.87M | -8.9% | +14.7% |
| Shares Outstanding | December 31, 2025 | 79.63M | +3.4% | +1.6% |
- Replimune Group, Inc. reported Net Income of -$247.30 million for fiscal year 2025.
- Replimune Group, Inc. showed a decrease of -14.6% in Net Income compared to the prior fiscal year.
- Replimune Group, Inc. reported Diluted EPS of $3.07 per share (loss) for fiscal year 2025.
- Replimune Group, Inc. showed an increase of +5.2% in Diluted EPS compared to the prior fiscal year.
- Replimune Group, Inc. reported Total Assets of $551.33 million for fiscal year 2025.
- Replimune Group, Inc. showed an increase of +13.0% in Total Assets compared to the prior fiscal year.
- Replimune Group, Inc. reported Cash and Equivalents of $111.12 million for fiscal year 2025.
- Replimune Group, Inc. showed an increase of +49.2% in Cash and Equivalents compared to the prior fiscal year.
- Replimune Group, Inc. reported Long-Term Debt of $46.38 million for fiscal year 2025.
- Replimune Group, Inc. showed an increase of +3.5% in Long-Term Debt compared to the prior fiscal year.
- Replimune Group, Inc. reported Stockholders Equity of $415.84 million for fiscal year 2025.
- Replimune Group, Inc. showed an increase of +11.0% in Stockholders Equity compared to the prior fiscal year.
- Replimune Group, Inc. reported R&D Expense of $189.45 million for fiscal year 2025.
- Replimune Group, Inc. showed an increase of +8.3% in R&D Expense compared to the prior fiscal year.
- Replimune Group, Inc. reported Operating Income of -$261.63 million for fiscal year 2025.
- Replimune Group, Inc. showed a decrease of -11.4% in Operating Income compared to the prior fiscal year.
- Replimune Group, Inc. reported Shares Outstanding of 77.09 million shares for fiscal year 2025.
- Replimune Group, Inc. showed an increase of +25.5% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: